Day: August 11, 2021

Pretax income of $13.9 million, a 199% increase over the prior year period Net income of $9.7 million, or $0.39 per diluted share New contract purchases of $286 million, a 39% increase over the first quarter of 2021LAS VEGAS, NV, Aug. 11, 2021 (GLOBE NEWSWIRE) — Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $9.7 million, or $0.39 per diluted share, for its second quarter ended June 30, 2021. This compares to net income of $3.0 million, or $0.13 per diluted share, in the second quarter of 2020. Revenues for the second quarter of 2021 were $66.8 million, compared to $67.3 million for the second quarter of 2020. Total operating expenses for the second quarter of 2021 were $52.9 million compared to $62.6 million for the 2020 period for a decrease of $9.8 million, or 15.6%....

– Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2021 – – Reported initial safety data from SL-172154 (SIRPα-Fc-CD40L) Phase 1 trial in ovarian cancer suggesting an encouraging early safety profile and ability to dose escalate beyond prior CD40 agonist antibodies – – Announced plans to study SL-172154 in hematologic malignancies, Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS), with an IND filing anticipated in the fourth quarter of 2021 – – Reported plans to continue dose escalating in the SL-279252 (PD1-Fc-OX40L) Phase 1 trial in advanced solid tumors based on trends in immune response data – AUSTIN, TX...

TORONTO, Aug. 11, 2021 (GLOBE NEWSWIRE) — Wesdome Gold Mines Ltd. (TSX: WDO) (“Wesdome” or the “Company”) today announces second quarter (“Q2 2021”) financial results. All figures are stated in Canadian dollars unless otherwise noted. Mr. Duncan Middlemiss, President and CEO commented, “Strong gold production in the second quarter of 30,375 ounces drove significant improvement in cost performance. Cash costs of $814 per ounce (US$663) and AISC of $1,240 (US$1,009), a decrease of 24% and 17% respectively over Q1 2021. H1 2021 production of 52,939 ounces, and cash costs of US$745 per ounce and AISC of US$1,085 per ounce has us well positioned to deliver on both our production and cost guidance for the year at Eagle River Mine Complex (92,000 – 105,000 ounces at cash costs of US$680 – 770 and AISC of US$980 – 1,090). Cash margins...

Q1 FY22 total revenue of $22.6 million growth of 10% compared to $20.5 million in Q1 FY21 Core growth platforms continue to perform, ecommerce solutions revenue grew by 15%, Strategic Sourcing grew by 15% and US-based Strategic Sourcing grew by 32% compared to Q1 FY21MONTREAL, Aug. 11, 2021 (GLOBE NEWSWIRE) — mdf commerce inc. (the “Corporation”) (TSX:MDF), a SaaS leader in digital commerce technologies, reported Q1 FY2022 financial results for its first quarter ended on June 30, 2021. Financial references are expressed in Canadian dollars unless otherwise indicated. “Q1 fiscal 2022 continued many of the positive trends seen throughout fiscal 2021,” said Luc Filiatreault, CEO of mdf commerce. “Our core growth platforms, Strategic Sourcing and ecommerce, both had double digit growth with our ecommerce solutions and US-based Strategic...

Initiated Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC); first interim safety data expected at end of 2021 and topline results mid-2022—Announces upcoming presentations to highlight final data from Aileron’s completed Phase 1b trial of ALRN-6924 in patients with small cell lung cancer (SCLC) and initial findings from ongoing Healthy Volunteer Study of ALRN-6924         ISEH 2021 Virtual Scientific Meeting (August 25-28, 2021) ESMO Congress 2021 (September 16-21, 2021)—ALRN-6924 is designed to deliver selective chemoprotection against chemotherapy-induced toxicities via p53 biomarker strategy        Nearly 1 million patients in the U.S. across all cancer types are diagnosed annually with p53-mutated cancer—$59.5...

CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and second quarter 2021 financial results. “This quarter we announced our shift to rapid enzymatic synthesis, or RES, for production of our closed-ended DNA, ceDNA, constructs and our signing of a lease to establish significant internal current Good Manufacturing Practice, or cGMP, manufacturing capacity. These are important steps toward our goal of extending the reach of our durable, redosable genetic medicines to patients with prevalent diseases,” said Geoff McDonough, M.D., chief executive officer of Generation Bio. “We will continue to advance the platform throughout the rest of the year and expect factor...

HOUSTON, Aug. 11, 2021 (GLOBE NEWSWIRE) — ION Geophysical Corporation (NYSE: IO) today reported revenues of $19.7 million in the second quarter 2021, a 40% increase compared to $14.0 million in the first quarter 2021 and a 13% decrease compared to $22.7 million one year ago. Net loss attributable to ION in the second quarter 2021 was $23.6 million, or a loss of $0.90 per share, compared to $5.2 million, or a loss of $0.37 per share in the second quarter 2020. Excluding special items in both periods, the Company reported an Adjusted net loss attributable to ION in the second quarter 2021 of $11.1 million, or a loss of $0.43 per share, compared to an Adjusted net loss attributable o ION of $12.1 million, or a loss of $0.85 per share in the second quarter 2020. The Company reported Adjusted EBITDA of $0.1 million for the second quarter...

– Second Quarter Revenues of $12.9 Million (down 0.6% yoy) And Share in NPI Revenue Interests of $8.5 Million (up 434% yoy) totaling $21.4 Million (up 47.0% yoy) – – Second Quarter Net Income of $0.11 Per Share – – Second Quarter Adjusted EBITDA1 of $8.3 Million (up 6.6% yoy) – – Raises Full Year 2021 Revenue and Share in NPI Revenues Interest Guidance to between $75 and $79 Million – LUXEMBOURG, Aug. 11, 2021 (GLOBE NEWSWIRE) — NeoGames S.A. (Nasdaq: NGMS) (“NeoGames” or the “Company”), a technology-driven provider of end-to-end iLottery solutions, announced today financial results for the second quarter ended June 30, 2021. Moti Malul, Chief Executive Officer of NeoGames, said: “We are increasingly encouraged by the performance and development of the various markets and customers we support, notwithstanding expected...